Anifa Avakian Stadtman
Optometrist · Chandler, AZNPI 1396154456
Payments from drug & device makers
Across 128 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$786
- Tarsus Pharmaceuticals, Inc.$395
- Alcon$361
- Novartis$199
- Oyster Point Pharma, Inc.$179
- Johnson & Johnson Vision Care, Inc.$177
- plus $880 from 11 others
What the payments were for
- Food & beverage$2,978100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $786 |
| Tarsus Pharmaceuticals, Inc. | 14 | $395 |
| Alcon | 9 | $361 |
| Novartis | 13 | $199 |
| Oyster Point Pharma, Inc. | 8 | $179 |
| Johnson & Johnson Vision Care, Inc. | 6 | $177 |
| Sun Pharmaceutical Industries Inc. | 8 | $173 |
| Biotissue Holdings Inc. | 4 | $139 |
| Lumenis BE Inc | 1 | $134 |
| Bausch & Lomb Americas Inc. | 4 | $87 |
| Mallinckrodt Hospital Products Inc. | 3 | $73 |
| Thea Pharma Inc. | 3 | $68 |
| Eyevance Pharmaceuticals LLC | 3 | $67 |
| Dompe US, Inc. | 2 | $62 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Glaukos Corporation | 1 | $30 |
| Akorn Operating Company LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$134
- Clareon$133
- XEN GLAUCOMA TREATMENT SYSTEM$121
- Acuvue$111
How this compares
$2,978 in reported general payments places this provider in the 85th percentile of 1,134 optometrist providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 28 | $24,942 |
| XdemvyLotilaner | 12 | $22,252 |
| MieboPerfluorohexyloctane/Pf | 14 | $11,378 |
| Cyclosporine | 14 | $4,549 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $417 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $181 |
| Azithromycin | 14 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $786 | $24,94228 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $395 | $22,25212 claims |
| Bausch & Lomb Americas Inc.Miebo | $87 | $11,37814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Chandler
- Catherine HollenbachChandler$10K
- Paul WagnerChandler$6K
- Marc BloomensteinScottsdale$2.3M
- Stephanie WooLake Havasu City$540K
- Kevin HelmuthSacaton$281K
- Christina SorensonGlendale$181K
- Jashpal RajasansiGilbert$120K
- Michelle Marie MijaresFort Defiance$38K
- Jamie KuhnGlendale$37K
- Tania SobchukLake Havasu City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.